Table 2
Lymphocyte activation markers in non-diverted and diverted intestinal mucosa
| IELs | LPLs | ||||||
|---|---|---|---|---|---|---|---|
| Non-diverted | Diverted | Non-diverted | Diverted | ||||
| Colon cancer 1 | |||||||
| CD25 | 0.5 | 0.2 | 1.6 | 2.2 | |||
| CD69 | 99.5 | 98.9 | 97 | 93.4 | |||
| Colon cancer 2 | |||||||
| CD25 | 2.0 | 0 | 2.6 | 1.6 | |||
| CD69 | 98.5 | 99.5 | 90.2 | 91.2 | |||
| Ulcerative colitis | |||||||
| CD25 | 1.3 | 0 | 0.7 | 0.4 | |||
| CD69 | 99.2 | 99.3 | 98.4 | 97.8 | |||
| Crohn's disease | |||||||
| CD25 | 1.3 | 0.4 | ND | ND | |||
| CD69 | 90.3 | 96.4 | ND | ND | |||
-
Results expressed as percentage of CD3 lymphocytes expressing the activation marker.
-
IEL, intraepithelial lymphocyte; LPL, lamina propria lymphocyte; ND, not determined.
